期刊文献+

洋地黄毒苷候选参考方法的建立及评价

Establishment and evaluation for the determination of serum digitoxin as a candidate reference method
下载PDF
导出
摘要 目的建立一种基于同位素稀释超高效液相色谱-串联质谱(ID-UPLC-MS/MS)的血清洋地黄毒苷检测候选参考方法,并对此方法进行性能评价。方法在血清中加入内标物质洋地黄毒苷-21,23,23-d_(3),采用0.5 mol/L硫酸锌溶液进行蛋白沉淀,采用叔丁基甲基醚对样本进行液液萃取,上清液采用氮气吹干,流动相复溶后采用ID-UPLC-MS/MS检测。采用五点包括法计算血清洋地黄毒苷水平。参考美国临床实验室标准化协会(CLSI)C62-A文件和CLSI EP15-A3文件对建立的ID-UPLC-MS/MS方法进行性能评价(基质效应、特异性、携带污染、精密度、准确度),同时评估其检测洋地黄毒苷的测量不确定度。结果建立的ID-UPLCMS/MS方法检测血清洋地黄毒苷的线性范围为2.8~94.9 nmol/L,批内变异系数(CV)为0.44~1.98%、总CV为0.41%~1.06%;加标回收率为100.03%~100.48%;检测限[信噪比(R_(SN))=3]及定量限(R_(SN)=10)分别为0.032和0.095 nmol/L;检测2020 RELA-A、2020 RELA-B样本,相对偏移分别为0.62%、0.29%,其中2020 RELA-A样本的不确定度为0.35 nmol/L。结论建立了检测血清洋地黄毒苷的ID-UPLC-MS/MS方法。该方法灵敏度高,重复性好,准确度高,有望作为人血清洋地黄毒苷测定的候选参考方法。 Objective To establish a candidate reference method for the determination of serum digitoxin based on isotope dilution ultra high performance liquid chromatography tandem mass spectrometry(ID-UPLC-MS/MS),and to evaluate the performance of this method.Methods The human serum was added with digitoxin-21,23,23-d_(3),the protein was precipitated in 0.5 mol/L zinc sulfate solution.Then the samples were extracted with tert-butyl methyl ether,the upper layer was dried with nitrogen flow.The residual was reconstituted with mobile phase and analyzed by ID-UPLC-MS/MS.Serum digitoxin concentration was calculated by 5-point bracketing method.The ID-UPLC-MS/MS(matrix effect,specificity,carrying contamination,precision,accuracy)was validated according to the Clinical and Laboratory Standards Institute(CLSI)C62-A and CLSI EP15-A3.The uncertainty of the measurement of digitoxin by ID-UPLC-MS/MS.Results The ID-UPLC-MS/MS for the determination of digitoxin was validated over a concentration range of 2.8-94.9 nmol/L.The intra-batch coefficient of variation(CV)was 0.44%-1.98%,and the total CV was 0.41%-1.06%.The recoveries were 100.03%-100.48%.The limits of detection[signal-to-noise ratio(R_(SN))=3]and quantitation(R_(SN)=10)were 0.032 and 0.095 nmol/L,respectively.According to RELA 2020,RELA-A and RELA-B 2020 relative biases of 0.62%and 0.29%were determined to be the uncertainty of 0.35 nmol/L.Conclusions The ID-UPLC-MS/MS established successfully for serum digitoxin has good precision,repeatability and accuracy,which can be used as a candidate reference method.
作者 唐宁波 刘冠财 刘晓雨 杨丰繁 龚志梅 孙可其 TANG Ningbo;LIU Guancai;LIU Xiaoyu;YANG Fengfan;GONG Zhimei;SUN Keqi(Department of Reference System,Mike Biology Co.,Ltd.,Chengdu 611731,Sichuan,China)
出处 《检验医学》 CAS 2022年第5期456-462,共7页 Laboratory Medicine
基金 国家重点研发计划资助项目(2019YFF0216500)。
关键词 洋地黄毒苷 同位素稀释超高效液相色谱-串联质谱 候选参考方法 方法学评价 Digitoxin Isotope dilution ultra high performance liquid chromatography tandem mass spectrometry Candidate reference method Methodological assessment
  • 相关文献

参考文献5

二级参考文献41

  • 1王淑娟,蔡卫民,郭洪斌.用荧光偏振免疫法和紫外法比较研究茶碱的人体药物动力学[J].中国医院药学杂志,1993,13(11):490-491. 被引量:10
  • 2李优鑫,毛静远,李惠芬.地高辛血药浓度检测方法的分析[J].中国中药杂志,2007,32(4):285-288. 被引量:11
  • 3MARTINDALE.The Extra Pharmacopoeia.31 版[M].,1996.856.
  • 4贺佑峰.放射免疫分析与相关技术进展[M].北京:原子能出版社,1996.1.
  • 5孙宝清,莫红樱,邱志辉,陈顺存,钟南山.高效液相色谱法和荧光偏振免疫法测定茶碱血药浓度方法的比较[J].广州医药,1997,28(1):10-11. 被引量:7
  • 6Vardas PE,Kanoupakis EM,Kochiadakis GE,et al.Effects of long-term digoxin therapy on heart variability,baroreceptor sensitivity and exercise capacity in patients with heart failure[J].Cardiolvasc Drugs Ther,1998,12(1):47-55.
  • 7Riaz K,Forker AD.Digoxin use in congestive heart fail ure[J].Drugs,1998,55(6):747.
  • 8The Digitalis Investigation Group (DIG).The effect of digoxin on mortality and morbidity in patients with hear failure[J].N Eng J Med,1997,336(8); 525-535.
  • 9Rich MW,McSherry F,Williford WO,et al.Effect of age on mortality,hospitalizations and respon to digoxin in patients with heart failure:the DIG study[J].Am Coll Cardiol,200,38(3):806-813.
  • 10Majumdar SR,McAlister FA,Cree M,et al.Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the Assessment of Treatment with Lisinopril and Survival (ATLAS) study[J].Clin Ther,2004,26(5):694-703.

共引文献81

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部